DORIDEN
LOE ApproachingNDAORALCAPSULEPriority Review
Approved
Apr 1957
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Data completeness
1/8 — Limited
Priority Review
Drug data last refreshed 9h ago · AI intelligence enriched 2w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
DORIDEN is an oral capsule small-molecule drug approved in 1957 by Sanofi under NDA. The generic name and mechanism of action are not publicly detailed in available data, limiting clinical characterization.
LOE Approaching
Product approaching loss of exclusivity with moderate competitive pressure (30), suggesting reduced team investment and potential headcount consolidation.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Career Relevance
Zero linked job openings and approaching LOE signal limited career opportunity on this product. Roles are primarily defensive, focused on maintaining existing customer relationships during market erosion rather than growth initiatives.
Brand ManagerField Sales Representative
Worked on DORIDEN at Sanofi? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.